Immunomedics (NASDAQ:IMMU) Receiving Somewhat Positive Media Coverage, Study Shows

Press coverage about Immunomedics (NASDAQ:IMMU) has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immunomedics earned a news impact score of 0.17 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.7297568318892 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ IMMU traded down $0.69 during midday trading on Friday, hitting $13.94. The stock had a trading volume of 1,608,244 shares, compared to its average volume of 1,966,683. The company has a market cap of $2,425.27, a PE ratio of -17.21 and a beta of 1.62. Immunomedics has a 52 week low of $5.00 and a 52 week high of $18.93. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.26 and a current ratio of 1.26.

Immunomedics (NASDAQ:IMMU) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.90 million. analysts forecast that Immunomedics will post -0.96 earnings per share for the current fiscal year.

A number of brokerages have weighed in on IMMU. ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub upgraded shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 25th. TheStreet upgraded shares of Immunomedics from a “d” rating to a “c-” rating in a report on Friday, February 9th. Jefferies Group upped their price objective on shares of Immunomedics from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Finally, Zacks Investment Research cut shares of Immunomedics from a “hold” rating to a “sell” rating in a report on Saturday, February 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $19.00.

In other news, Director David M. Goldenberg sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total value of $350,000.00. Following the transaction, the director now owns 1,774,285 shares in the company, valued at $31,049,987.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David M. Goldenberg sold 17,729 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $17.09, for a total transaction of $302,988.61. Following the transaction, the director now owns 1,774,285 shares in the company, valued at approximately $30,322,530.65. The disclosure for this sale can be found here. In the last quarter, insiders sold 77,729 shares of company stock worth $1,342,589. Insiders own 14.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Immunomedics (NASDAQ:IMMU) Receiving Somewhat Positive Media Coverage, Study Shows” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-immunomedics-immu-stock-price.html.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.

Insider Buying and Selling by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply